Umutesi J, et al. - Experts examined data gathered during programmatic screening activities conducted in 2017 in order to explain the hepatitis C virus (HCV, a leading cause of chronic liver disease, cirrhosis, and liver cancer, contributing to an expanding burden of mortality) seroprevalence in the general population and to recognize associated factors. HCV screening was arranged within each of the 30 districts in Rwanda. HCV antibodies and HCV RNA VL were the two markers that were examined. Out of a total of 124,223 people who were screened, 11,003 were found positive for anti-HCV. Anti-HCV prevalence differed by age with the oldest age group (> 55-year-olds) and the youngest age group (< 25-year-olds) with a prevalence of 16.46% and 2.20%, respectively. A correlation persisted among anti-HCV prevalence and age, province and socioeconomic status, post-adjustment for covariates. Of the 3,771 anti-HCV-positive individuals who had an available HCV RNA VL result, 2,099 were observed with a detectable HCV RNA VL. Also, a relationship between the age and HCV viremia was discovered. Hence, over 55% of people who had positive screening results for HCV-antibodies were concluded as chronically infected. Moreover, among older individuals, targeted screening for HCV is suggested, given the association between age and infection. As Rwanda advances towards HCV exclusion, more geographical hotspots of HCV infection could also notify targeted screening.